← Back to Screener
ProMIS Neurosciences Inc. Common Shares (ON) (PMN)
Price$11.45
Favorite Metrics
Price vs S&P 500 (26W)-11.51%
Price vs S&P 500 (4W)-43.73%
Market Capitalization$24.63M
All Metrics
Book Value / Share (Quarterly)$4.27
P/TBV (Annual)5.79x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-12.80
Price vs S&P 500 (YTD)63.64%
Net Profit Margin (TTM)-12900.00%
EPS (TTM)$-18.46
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-18.46
EPS (Annual)$-1.07
ROI (Annual)-352.02%
Net Profit Margin (5Y Avg)-12306.41%
Cash / Share (Quarterly)$7.17
ROA (Last FY)-97.01%
EBITD / Share (TTM)$-3.36
ROE (5Y Avg)-725.53%
Operating Margin (TTM)-12900.00%
Cash Flow / Share (Annual)$-20.79
P/B Ratio2.68x
P/B Ratio (Quarterly)2.49x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-5.53x
ROA (TTM)-184.39%
EPS Incl Extra (Annual)$-1.07
Current Ratio (Annual)8.52x
Quick Ratio (Quarterly)1.27x
3-Month Avg Trading Volume0.13M
52-Week Price Return-28.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.20
P/S Ratio (Annual)2463.42x
Asset Turnover (Annual)0.01x
52-Week High$39.75
Operating Margin (5Y Avg)-12266.41%
EPS Excl Extra (Annual)$-1.07
26-Week Price Return-4.63%
Quick Ratio (Annual)6.03x
13-Week Price Return40.43%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.76x
Enterprise Value$9.235
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-46400.00%
Cash / Share (Annual)$10.19
3-Month Return Std Dev118.86%
Net Income / Employee (TTM)$-5
ROE (Last FY)-352.02%
EPS Basic Excl Extra (Annual)$-1.07
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-18.46
Receivables Turnover (Annual)0.29x
ROI (TTM)-163.59%
P/S Ratio (TTM)2463.42x
Pretax Margin (5Y Avg)-12306.41%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.97
Price vs S&P 500 (52W)-63.10%
Year-to-Date Return67.57%
5-Day Price Return-5.02%
EPS Normalized (Annual)$-1.07
ROA (5Y Avg)-229.81%
Net Profit Margin (Annual)-46400.00%
Month-to-Date Return-9.88%
Cash Flow / Share (TTM)$-1.78
EBITD / Share (Annual)$-1.18
Operating Margin (Annual)-46300.00%
LT Debt / Equity (Annual)0.69x
ROI (5Y Avg)-711.40%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-18.46
P/TBV (Quarterly)5.79x
P/B Ratio (Annual)1.88x
Pretax Margin (TTM)-12900.00%
Book Value / Share (Annual)$12.61
Price vs S&P 500 (13W)38.05%
Beta-0.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-163.59%
52-Week Low$6.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PMNProMIS Neurosciences Inc. Common Shares (ON) | 2463.42x | — | — | — | $11.45 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The company uses its proprietary ProMIS platform to identify and target toxic misfolded proteins that drive neurodegeneration.